Characteristics of patients with chronic obstructive pulmonary disease (COPD) and smoking-related phenotypes studied
| Cohort | ||||
| NETT n=362* | Norway n=851* | ECLIPSE n=1734* | COPDGene n=494* | |
| Characteristics | ||||
| Men*, n (%) | 234 (64.6) | 511 (60.0) | 1160 (66.9) | 242 (49.0) |
| Age in years*, Mean (SD) | 67.4 (5.8) | 65.5 (10.1) | 63.7 (7.1) | 64.7 (8.1) |
| Pack-years smoked*, Mean (SD) | 66.1 (30.9) | 32.1 (18.6) | 50.4 (27.4) | 54.8 (26.8) |
| Post-bronchodilator FEV1 (% pred.)*, Mean (SD) | 29.1 (7.8) | 50.7 (17.5) | 44.8 (14.7) | 48.7 (18.4) |
| Post-bronchodilator FEV1/FVC*, Mean (SD) | 0.32 (0.06) | 0.51 (0.13) | 0.45 (0.12) | 0.48 (0.13) |
| Enrolment, Years | 1998–2002 | 2003–2005 | 2005–2007 | 2008–2009 |
| Genotyping technology, Chip | Illumina Quad 610 | Illumina HumanHap 550 V1, V3, and Duo | Illumina HumanHap 550 V3 | Illumina Human Omni1-Quad |
| Phenotype studied | ||||
| Age at smoking initiation | ||||
| Mean (SD) | 16.6 (3.6) | 18.7 (5.1) | 16.9 (4.4) | 16.8 (4.4) |
| Number of patients with non-missing phenotype | 362 | 851 | 1690 | 494 |
| Lambda inflation factor | 0.986 | 0.989 | 1.019 | 0.997 |
| Lifetime average CPD | ||||
| Mean (SD) | 32.4 (13.5) | 15.7 (7.8) | 25.5 (12.4) | 27.6 (11.8) |
| Number of patients with non-missing phenotype | 361 | 851 | 1734 | 494 |
| Lambda inflation factor | 1.002 | 0.996 | 1.018 | 0.996 |
| Smoking cessation | ||||
| Current smokers, n (%) | 0 (0) | 404 (47.5) | 610 (35.3) | 150 (30.6) |
| Former smokers, n (%) | 362 (100) | 447 (52.5) | 1120 (64.7) | 340 (69.4) |
| Lambda inflation factor | – | 1.000 | 0.998 | 0.995 |
| Current CPD† | ||||
| Mean (SD) | – | 13.1 (6.9) | 15.6 (10.8) | 18.4 (12.4) |
| Number of patients with non-missing phenotype | – | 398 | 565 | 150 |
| Lambda inflation factor | – | 0.995 | 1.005 | 0.997 |
* Calculated for patients with at least one non-missing phenotype.
† For patients with reported current CPD >0.
CPD, number of cigarettes smoked per day; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NETT, National Emphysema Treatment Trial.